tbuckley/cabot-search huggingface dataset:
Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data
Authors: Yuanyuan Liang, Amanda J Driscoll, Priyanka D Patel, Shrimati Datta, Merryn Voysey, Neil French, Leslie P Jamka, Marc Y R Henrion, Latif Ndeketa, Matthew B Laurens, Robert S Heyderman, Melita A Gordon, Kathleen M Neuzil
Journal: The Lancet Global Health (2022)

Typhoid conjugate vaccines are being introduced in low-income and middle-income countries to prevent typhoid illness in children. Vaccine effectiveness studies assess vaccine performance after introduction. The test-negative design is a commonly used method to estimate vaccine effectiveness that has not been applied to typhoid vaccines because of concerns over blood culture insensitivity. The overall aim of the study was to evaluate the appropriateness of using a test-negative design to assess typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TT) effectiveness using a gold standard randomised controlled trial database.Using blood culture data from a randomised controlled trial of Vi-TT in Malawi, we simulated a test-negative design to derive vaccine effectiveness estimates using three different approaches and compared these to randomised trial efficacy results. In the randomised trial, 27 882 children aged 9 months to 12 years were randomly assigned (1:1) to receive a single dose of Vi-TT or meningococcal capsular group A conjugate vaccine between Feb 21 and Sept 27, 2018, and were followed up for blood culture-confirmed typhoid fever until Sept 30, 2021.For all three test-negative design approaches, vaccine effectiveness estimates (test-negative design A, 80·3% [95% CI 66·2 to 88·5] vs test-negative design B, 80·5% [66·5 to 88·6] vs test-negative design C, 80·4% [66·9 to 88·4]) were almost identical to the randomised trial results (80·4% [95% CI 66·4 to 88·5]). Receipt of Vi-TT did not affect the risk of non-typhoid fever (vaccine efficacy against non-typhoid fever -0·4% [95% CI -4·9 to 3·9] vs -1% [-5·6 to 3·3] vs -2·5% [-6·4 to 1·3] for test-negative design A, test-negative design B, and test-negative design C, respectively).This study validates the test-negative design core assumption for typhoid vaccine effectiveness estimation and shows the accuracy and precision of the estimates compared with the randomised controlled trial. These results show that the test-negative design is suitable for assessing typhoid conjugate vaccine effectiveness in post-introduction studies using blood culture surveillance.Bill & Melinda Gates Foundation.
Correction: ESPNIC clinical practice guidelines: intravenous maintenance fluid therapy in acute and critically ill children—a systematic review and meta-analysis
Authors: David W. Brossier, Lyvonne N. Tume, Anais R. Briant, Corinne Jotterand Chaparro, Clémence Moullet, Shancy Rooze, Sascha C. A. T. Verbruggen, Luise V. Marino, Fahad Alsohime, Sophie Beldjilali, Fabrizio Chiusolo, Leonardo Costa, Capucine Didier, Stavroula Ilia, Nyandat L. Joram, Martin C. J. Kneyber, Eva Kühlwein, Jorge Lopez, Jesus López-Herce, Huw F. Mayberry, Fortesa Mehmeti, Magdalena Mierzewska-Schmidt, Maria Miñambres Rodríguez, Claire Morice, John V. Pappachan, Florence Porcheret, Leonor Reis Boto, Luregn J. Schlapbach, Hakan Tekguc, Konstantinos Tziouvas, Jean-Jacques Parienti, Isabelle Goyer, Frederic V. Valla
Journal: Intensive Care Medicine (2022)
Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study
Authors: Bruno Hernaez, Ana Muñoz-Gómez, Africa Sanchiz, Eva Orviz, Adrian Valls-Carbo, Iñigo Sagastagoitia, Oskar Ayerdi, Rocío Martín, Teresa Puerta, Mar Vera, Noemi Cabello, Jorge Vergas, Cristina Prieto, María Pardo-Figuerez, Anabel Negredo, José María Lagarón, Jorge del Romero, Vicente Estrada, Antonio Alcamí
Journal: The Lancet Microbe (2022)

The transmission of monkeypox virus occurs through direct contact, but transmission through saliva or exhaled droplets and aerosols has not yet been investigated. We aimed to assess the presence of monkeypox virus DNA and infectious virus in saliva samples and droplets and aerosols exhaled from patients infected with monkeypox virus.We did a cross-sectional study in patients with monkeypox confirmed by PCR who attended two health centres in Madrid, Spain. For each patient, we collected samples of saliva, exhaled droplets within a mask, and aerosols captured by air filtration through newly developed nanofiber filters. We evaluated the presence of monkeypox virus in the samples by viral DNA detection by quantitative PCR (qPCR) and isolation of infectious viruses in cell cultures.Between May 18 and July 15, 2022, 44 patients with symptomatic monkeypox attended two health centres in Madrid and were included in the study. All were cisgender men, with a median age of 35·0 years (IQR 11·3). We identified high loads of monkeypox virus DNA by qPCR in 35 (85%) of 41 saliva samples. Infectious monkeypox virus was recovered from 22 (67%) of 33 saliva samples positive for monkeypox virus DNA. We also found a significant association between the number of affected cutaneous areas or general symptoms and the viral load present in saliva samples. Droplets exhaled from patients with monkeypox, detected inside a mask, contained monkeypox virus DNA in 32 (71%) of 45 samples, with two of the 32 positive samples showing the presence of the infectious virus. Monkeypox virus DNA in aerosols, collected from the medical consultation room, were detected in 27 (64%) of 42 samples, despite patients wearing an FFP2 mask during the visit. Infectious virus was not recovered from aerosol samples. High levels of monkeypox virus DNA were identified in aerosols collected from a hospital isolation room housing a patient with monkeypox.The identification of high viable monkeypox virus loads in saliva in most patients with monkeypox and the finding of monkeypox virus DNA in droplets and aerosols warrants further epidemiological studies to evaluate the potential relevance of the respiratory route of infection in the 2022 monkeypox virus outbreak.EU, Consejo Superior de Investigaciones Científicas, and Ciberinfec.
Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial
Authors: Manish D Sinha, Haotian Gu, Abdel Douiri, Janette Cansick, Eric Finlay, Rodney Gilbert, Larissa Kerecuk, Andrew Lunn, Heather Maxwell, Henry Morgan, Mohan Shenoy, Rukshana Shroff, Pushpa Subramaniam, Jane Tizard, Yincent Tse, Reza Rezavi, John M Simpson, Phil J Chowienczyk
Journal: The Lancet Child & Adolescent Health (2022)
Bioactive MXene Promoting Angiogenesis and Skeletal Muscle Regeneration through Regulating M2 Polarization and Oxidation Stress
Authors: Ting Li, Junping Ma, Wensi Wang, Bo Lei
Journal: Advanced Healthcare Materials (2022)

Abstract Complete repair of skeletal muscles caused by severe mechanical damage and muscle‐related diseases remains a challenge. 2D Ti 3 C 2 T x (MXene) possesses special photoelectromagnetic properties and has attracted considerable attention in materials science and engineering. However, the bioactive properties and potential mechanism of MXene in tissue engineering, especially in skeletal muscle regeneration, are unclear. Herein, the antioxidation and anti‐inflammation activities of MXene and its effects on myogenic differentiation and regeneration of skeletal muscle in vivo are investigated. In vitro studies have shown that MXene has excellent antioxidation and anti‐inflammatory properties, and promotes myogenic differentiation and angiogenesis. MXene can remove excess reactive oxygen species in macrophage cells to alleviate oxidative stress and induce the transformation of M1 macrophages into M2 macrophages to reduce excessive inflammation, which can significantly promote the proliferation and differentiation of myoblasts, as well as the proliferation, migration, and tube formation of endothelial cells. Animal experiments with rat tibial anterior muscle defects show that MXene can promote angiogenesis, muscle fiber formation, and skeletal muscle regeneration by regulating the cell microenvironment through anti‐inflammatory and antioxidant pathways. The findings suggest that MXene can be used as a multifunctional bioactive material to enhance tissue regeneration through robust antioxidation, anti‐inflammation, and angiogenesis activities.
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Authors: Austin R. Pantel, Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K. Weeks, Drew A. Torigian, Chia-Ju Hsieh, Benjamin Ferman, Nawar A. Latif, Janos L. Tanyi, Lainie P. Martin, Shannon M. Lanzo, Fang Liu, Quy Cao, Gordon B. Mills, Robert K. Doot, David A. Mankoff, Robert H. Mach, Lilie L. Lin, Fiona Simpkins
Journal: Clinical Cancer Research (2022)

Abstract Purpose: PARP inhibitors have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi. Biomarkers to predict response are needed. [18F]FluorThanatrace ([18F]FTT) is a PARPi-analog PET radiotracer that noninvasively measures PARP-1 expression. Herein, we evaluate [18F]FTT as a biomarker to predict response to PARPi in patient-derived xenograft (PDX) models and subjects with HRD HGSOC. Experimental Design: In PDX models, [18F]FTT-PET was performed before and after PARPi (olaparib), ataxia-telangiectasia inhibitor (ATRi), or both (PARPi-ATRi). Changes in [18F]FTT were correlated with tumor volume changes. Subjects were imaged with [18F]FTT-PET at baseline and after ∼1 week of PARPi. Changes in [18F]FTT-PET uptake were compared with changes in tumor size (RECISTv1.1), CA-125, and progression-free survival (PFS). Results: A decrease in [18F]FTT tumor uptake after PARPi correlated with response to PARPi, or PARPi-ATRi treatment in PARPi-resistant PDX models (r = 0.77–0.81). In subjects (n = 11), percent difference in [18F]FTT-PET after ∼7 days of PARPi compared with baseline correlated with best RECIST response (P = 0.01), best CA-125 response (P = 0.033), and PFS (P = 0.027). All subjects with &amp;gt;50% reduction in [18F]FTT uptake had &amp;gt;6-month PFS and &amp;gt;50% reduction in CA-125. Utilizing only baseline [18F]FTT uptake did not predict such responses. Conclusions: The decline in [18F]FTT uptake shortly after PARPi initiation provides a measure of drug-target engagement and shows promise as a biomarker to guide PARPi therapies in this pilot study. These results support additional preclinical mechanistic and clinical studies in subjects receiving PARPi ± combination therapy. See related commentary by Liu and Zamarin, p. 1384
Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis
Authors: Sharmila Raghunandan, Lev Gorfinkel, Michael Graiser, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Scott Gillespie, Adrianna Lynn Westbrook, Kirsten M. Williams, Michelle Schoettler, Amelia Langston, Leslie Kean, Muna Qayed, John T. Horan, Benjamin Watkins
Journal: Blood (2022)
CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
Authors: Bertram Glass, Anna Sureda, Ariane Boumendil, Peter Dreger, Paolo Corradini, Ron Ram, Nicolaus Kroeger, Luca Castagna, Thomas Pabst, Mi Kwon, Gerald Wulf, Alejandro Martín García-Sancho, Carlos Solano, Matthias Stelljes, Hans Christian Reinhardt, Marie Thérèse Rubio, Ram Malladi, Didier Blaise, Caroline Besley, Edouard Forcade, Malte von Bonin, Jürgen Finke, Inken Hilgendorf, Joaquín Martínez-López, Jose A. Perez-Simon, Wolfgang Bethge, Norbert Schmitz
Journal: Blood (2022)
Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide
Authors: Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, H. Kent Holland, Lawrence E. Morris, Asad Bashey, Melhem Solh
Journal: Blood (2022)
Mitochondrial Transfer to Host Cells from <i>Ex Vivo</i> Expanded Donor Hematopoietic Stem Cells
Authors: Hiroki Kawano, Yuko Kawano, Matthew J. McArthur, Laura M. Calvi, Satoshi Gojo, Scott W. Ballinger, Charles O. Smith, Roman A. Eliseev, Mark W. LaMere, Michael W. Becker
Journal: Blood (2022)
Real-World Outcomes with CD19 CAR T-Cell Therapy for B-Cell Malignancies in Regional/Rural Australia: Results from the Queensland CAR T-Cell Program
Authors: Nilu Perera, Ashleigh P Scott, Stewart Hunt, Cameron Curley, Siok-Keen Tey, Jason Butler, Andrea S Henden, Elango S. Pillai, Cheryl Hutchins, Kari Louise Mudie, Glen A Kennedy
Journal: Blood (2022)
Perspectives of Older Patients with Blood Cancers, Caregivers, and Oncology Clinicians on Benefits and Barriers of Technology for Home Functional Assessment
Authors: Dillon D. Clancy, Anna C. Revette, Nupur E. Bahl, Kristi Ho, Brad Manor, Marcia Testa, Christina M. Dieli-Conwright, Tammy T. Hshieh, Jane A. Driver, Gregory A. Abel, Clark Dumontier
Journal: Blood (2022)
Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT
Authors: Annalisa Paviglianiti, Alberto Mussetti, Maud Ngoya, Ariane Boumendil, Zafer Gulbas, Fabio Ciceri, Francesca Bonifazi, Domenico Russo, Nathalie Fegueux, Friedrich Stölzel, Claude-Eric Bulabois, Gerard Socie, Edouard Forcade, Carlos Solano, Hervé Finel, Stephen Robinson, Silvia Montoto, Bertram Glass
Journal: Blood (2022)
CAR T Cells and Their Immune Environment Synergize to Shape Distinct Immune Profiles in Response Versus Toxicity in B Cell Lymphoma Patients
Authors: Stefanie Kreutmair, Maximilian M Schaefer, Sebastian Stolz, Carla Merten, Can Ulutekin, Florian Ingelfinger, Susanne Unger, Chiara Alberti, Tobias Wertheimer, Aakriti Sethi, Thorsten Zenz, Markus G Manz, Antonia Maria Susanne Müller, Corinne C Widmer, Burkhard Becher
Journal: Blood (2022)
Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia
Authors: Manuel Quadri, Claudia Saitta, Sonia Palamini, Chiara Palmi, Jia-Wey Tu, Sanil Bhatia, Arndt Borkhardt, Andrea Biondi, Giovanni Cazzaniga, Grazia Fazio
Journal: Blood (2022)
Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd
Authors: Ruihao Huang, Ting Chen, Sanbin Wang, Jishi Wang, Yi Su, Jing Liu, Peiyan Kong, Cheng Zhang, Lei Gao, Li Gao, Xi Zhang
Journal: Blood (2022)
Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
Authors: Valentin Letailleur, Amandine Le Bourgeois, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Maxime Jullien, Marianne Coste-Burel, Marie C Béné, Patrice Chevallier
Journal: Blood (2022)
Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
Authors: Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini
Journal: Blood (2022)
Financial Impact of Imatinib Discontinuation in Brazil - a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution
Authors: Renato Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Joyce Barreto Marques da Rosa Ferreira, Iohanã Gabriely Costa Oliveira, Luana Correa Travassos, Caroline Jorge Espadas, Tamyres Alves Gomes, Mariana Nascimento Caiaffo Rodrigues, Adelson Alves Silva
Journal: Blood (2022)
Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies
Authors: Frederick L. Locke, Sattva S. Neelapu, Markqayne D. Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R. Patel, Olalekan O. Oluwole
Journal: Blood (2022)
MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
Authors: Shaji K Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos
Journal: Blood (2022)
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience
Authors: Dorela Lame, Marianeve Caprino, Elena Marinelli Busilacchi, Nadia Viola, Erika Morsia, Michelangelo Pianelli, Shahram Kordasti, Attilio Olivieri, Antonella Poloni
Journal: Blood (2022)
Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial
Authors: Yue Tan, Jing Pan, Biping Deng, Zhuojun Ling, Song Weiliang, Zhenglong Tian, Ming Cao, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, Chunyu Li
Journal: Blood (2022)
Prevalence of Sars-Cov-2 in Stem Cell Donors from Anthony Nolan UK Stem Cell Registry: Sars-Cov-2 Testing Programme, Impact on Stem Cell Collections and Managing Risk Going Forward
Authors: Angharad Pryce, Ruta Maniusyte, Paul Johnson, Laura Hitchinson, Ann O'leary, Antonio Pagliuca, Rachel Pawson, Robert David Danby, Chloe Anthias
Journal: Blood (2022)
Programmed Death-1 Homolog (PD-1H/VISTA) Blockade Confers a Synergistic Anti-Leukemia Effect with PD-1 Blockade
Authors: Tae Kon Kim, Xue Han, Qianni Hu, Carly Hedgepath, Junshik Hong, Jihyun Park, Emily F Mason, Lieping Chen
Journal: Blood (2022)
Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
Authors: Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao
Journal: Blood (2022)
Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study
Authors: Alessandro Bosi, Bruno Fattizzo, Lorenzo Rizzo, Silvia Ferrari, Federico Lussana, Lorenza Maria Borin, Andrea Castelli, Paola Bianchi, Wilma Barcellini, Roberto Cairoli, Alfredo Molteni, Marta Riva
Journal: Blood (2022)
A Human iPSC Model Reveals Specific Upregulation of Linker Histone H1-0 in <i>ETV6::RUNX1</i>+ Preleukemia and B Cell Precursor Acute Lymphoblastic Leukemia
Authors: Vera H Jepsen, Daniel Hein, Daniel Picard, Tobias Lautwein, Rabea Wagener, Nan Qin, Annika Filip, Merja Heinäniemi, Arndt Borkhardt, Ute Fischer
Journal: Blood (2022)
Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder
Authors: Reid M. Muenzen, Mitchell E. Hughes, Sunita Dwivedy Nasta, Jakub Svoboda, Daniel J. Landsburg, Stefan K. Barta, Donald Tsai, Stephen J. Schuster, Elise A. Chong
Journal: Blood (2022)
Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
Authors: Aneeqa A Zafar, Chiung-Yu Huang, Mimi Lo, Jen Knoche, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee
Journal: Blood (2022)
Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Authors: Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S. Grover, Renu Balyan, Cliff Ding, Aung Myo, Ivan D. Horak, Helen E. Heslop
Journal: Blood (2022)
Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr
Authors: Lanping Xu, Yue Lu, Jing Chen, Shuwen Sun, Shaoyan Hu, Shunqing Wang, Xuedong Wu, Yuan Sun, Dingming Wan, Yajing Xu, Hui Jiang, Chunfu Li, Mei Lan, Erlie Jiang, Fei Li, Sixi Liu, Yongmin Tang, Fan Lin, Peihua Lu, Chengjuan Luo, Xiaojun Huang
Journal: Blood (2022)
Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses
Authors: Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva
Journal: Blood (2022)
Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
Authors: Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal
Journal: Blood (2022)
Single Cell Analysis Highlights Th17-Polarized CD4+ Naive T Cells with JAK3/STAT3 Pathway Activation in Pediatric Severe Aplastic Anemia
Authors: Jingliao Zhang, Tianfeng Liu, Yanxia Chang, Yongjuan Duan, Chao Liu, Xiaoyan Chen, Cheng Tao, Xiaofan Zhu, Yingchi Zhang
Journal: Blood (2022)
Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Sebastian E. Koschade, Kevin Klann, Shabnam Shaid, Binje Vick, Jan A. Stratmann, Marlyn Thölken, Laura M. Meyer, The Duy Nguyen, Julia Campe, Laura M. Moser, Susanna Hock, Fatima Baker, Christian Meyer, Frank Wempe, Hubert Serve, Evelyn Ullrich, Irmela Jeremias, Christian Münch, Christian H. Brandts
Journal: Blood (2022)
Primary HSPC-Derived Monocytes with <i>DNMT3A</i> p.R882H Exhibit Activated Myeloid Cell Gene Signatures
Authors: Alexander J. Silver, Donovan J. Brown, Maria P. Arrate, Yu Wang, Melissa A. Fischer, Pawan Bhat, J. Brett Heimlich, Alexander G. Bick, P. Brent Ferrell, Yaomin Xu, Michael R. Savona
Journal: Blood (2022)
Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training
Authors: Anna Kress, Benjamin Lu, Ayesha Butt, Jana Christian, Nikolai A. Podoltsev, Michael Hurwitz, Sarah Goldberg, Barbara Burtness, Iris Isufi, Darin Latimore, Alfred I. Lee, Pamela Kunz
Journal: Blood (2022)
Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM)
Authors: Tiantian Zhang, Zhe Wang, Soung-chul Cha, Aaron Anderson, Jingwei Liu, Zhenyuan Dong, Szymon Szymura, Benjamin Kuang, Elizabeth Oh, Sattva S. Neelapu, Larry W. Kwak
Journal: Blood (2022)
Phase I Study Evaluating Outcomes of Autologous HIV-Specific T Cells Targeting Non-Escaped Epitopes (HST-NEET) Therapy in HIV+ Individuals on ART (NCT03485963)
Authors: Danielle K. Sohai, Michael Keller, Patrick J. Hanley, Anushree Datar, Emily Reynolds, Dennis Copertino, Chase McCann, Haili Lang, Cecilia Motta, Andrew Wilson, Rebecca Lynch, Winiffer Conce Alberto, Zabrina L. Brumme, Natalie N. Kinloch, Conrad Russell Y. Cruz, Lynsay MacLaren Ehui, Sarah Henn, R. Brad Jones, Catherine M Bollard
Journal: Blood (2022)
Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy
Authors: Kevin Tang, Raamis Khwaja, Lei Feng, Paolo Strati, Raphael E. Steiner, Ranjit Nair, Christopher R. Flowers, Neeraj Saini, Jeremy L. Ramdial, Samer A. Srour, Richard E. Champlin, Gabriela Rondon, Janet Torres, Partow Kebriaei, Loretta J. Nastoupil, Haleigh Mistry, Elizabeth J. Shpall, Yago Nieto, Jason Westin, Sattva S. Neelapu, Sairah Ahmed
Journal: Blood (2022)